Company news

Pharvaris N.V. news in 2026

Pharvaris N.V.'s news releases, calls and decks from 2026, newest first.

View company

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

October 29, 2026

Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy

October 5, 2026

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks

September 8, 2026

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

September 3, 2026

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

August 12, 2026

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

July 22, 2026

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

July 5, 2026

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

June 15, 2026

Pharvaris Announces Annual General Meeting of Shareholders

June 11, 2026

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

May 28, 2026

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 11, 2026

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

May 8, 2026

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

April 20, 2026

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

April 1, 2026

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

March 10, 2026

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

March 2, 2026

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

February 10, 2026

Pharvaris Outlines 2026 Strategic Priorities

January 12, 2026

Decks in 2026